Mosaic Intelligence Labs, a surgical robotics startup, came out of stealth on Nov. 10 with $47 million in seed funding, which The Next Web reported was raised across two seed rounds. The company is building AI-guided catheters for blood-vessel procedures.
Who backed it
The Next Web, citing reporting by The Information, identified 8VC and Fundomo as the lead investors. Mosaic's Business Wire release is less specific. It assigns no lead roles and does not say which firm led which round, though it names Lingotto Innovation and Obvious Ventures among its backers and describes that list as non-exhaustive.
CEO Ileana Pirozzi also named A in her launch post, and A lists Mosaic Intelligence in its portfolio.
Much else about the financing remains opaque. Either the company declined to disclose them or the materials reviewed did not provide them: a valuation, round-by-round amounts, closing dates, ownership stakes and board appointments. Nor is there any breakdown of how the money will be divided among staffing, hardware development, clinical work and manufacturing.
What Mosaic is building
According to The Next Web, Mosaic is developing a semi-autonomous catheter whose tip bends to follow the intended vascular route while the surgeon advances it. That is a narrower proposition than fully autonomous surgery, and the distinction matters: the surgeon stays in the loop.
The company release describes a continuously updated three-dimensional view of anatomy and instrument location as the intended display. Longer-term, it mentions treatment categories such as targeted delivery of drugs, energy, biologics and other therapies.
Mosaic says it hopes to reduce, and eventually replace, reliance on ionizing X-ray guidance. That is a goal, not a documented present capability. The funding announcement likewise frames safer navigation and lower radiation exposure as development objectives rather than demonstrated patient-outcome findings.
